• (+5411) 3965-8409
  • This email address is being protected from spambots. You need JavaScript enabled to view it.

Active Studies

ENSEMBLE


VAC31518COV3001; fase 3

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older.

This study is being conducted under the sponsorship of Janssen (Janssen Vaccines & Prevention B.V) in collaboration with Operation Warp Speed (OWS), which also encompasses the Biomedical Advanced Research and Development Authority (BARDA), the National Institutes of Health (NIH), and the COVID-19 Prevention Trials Network (COVPN)

The primary objective of this study is to demonstrate the efficacy of Ad26.COV2.S in the prevention of molecularly confirmed, moderate to severe/critical coronavirus disease-2019 (COVID-19), as compared to placebo, in SARS-CoV-2 seronegative adults. Ad26.COV2.S (previously known as Ad26COVS1) is a monovalent vaccine composed of a recombinant, replication-incompetent adenovirus type 26 (Ad26) vector, constructed to encode the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike (S) protein.

HPTN 083
COHIVE
MOSAICO
ITAC
DEFT
START
FLU003 PLUS
ACTIV-01
COVPN 5001
TELEMEDICINE
TICO

CICAL

Urquiza 358, Balvanera (CP 1215).
Ciudad Autónoma de Buenos Aires, Argentina

Tel.: (+5411) 3965-8409

A nonprofit project of

Contact

© 2022 CICAL. Todos los derechos reservados.